NextBioMedical Applies for New Medical Technology Evaluation of Genicular Artery Embolization for Knee Osteoarthritis

NextBioMedical has applied to the National Evidence-based Healthcare Collaborating Agency (NECA) for a domestic evaluation of new medical technology regarding genicular artery embolization (GAE) for patients with knee osteoarthritis.

According to NextBioMedical on June 24, the new medical technology evaluation is a system that verifies the safety and clinical efficacy of emerging medical technologies. Based on the evaluation results, an institutional foundation is established for these technologies to be used in clinical practice. This application is part of the process to expand the clinical application of genicular artery embolization in South Korea.

Genicular artery embolization is an interventional procedure that selectively embolizes abnormal neovessels involved in generating intra-articular pain. This application for new medical technology evaluation is the first step toward objectively verifying the clinical value and domestic introduction potential of knee GAE through NECA's safety and efficacy assessment. Furthermore, it is expected to serve as an important opportunity to broaden the clinical application scope of musculoskeletal embolization beyond arthritis treatment.

In fact, overseas, active clinical studies are being conducted not only for knees but also for various joint diseases and tendon disorders of the shoulder, elbow, and hip, as well as for musculoskeletal conditions related to sports injuries. If further clinical evidence is accumulated and demand in medical practice increases, the application range of musculoskeletal embolization is expected to gradually expand.

A representative from NextBioMedical stated, "This application for new medical technology evaluation is an important first step to assess the potential for clinical application of genicular artery embolization for patients with knee osteoarthritis in Korea," adding, "Starting with GAE, we plan to expand indications to a wider range of joint and musculoskeletal diseases and continuously build relevant clinical evidence."

This content was produced with the assistance of AI translation services.